Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Joan Osland Graffius who wrote (98437)	3/29/2003 6:40:18 PM
From: Knighty Tin	Read Replies (2) \| Respond to of 132070

Joan, that's similar to what he was saying last week. He still hates US stocks longer term and loves commodities. But he thinks the inevitable victory in Iraq will push up stocks and the dollar and zap commodities. I agree, unless we have to move from Baghdad to Damascus and Tehran, then to Poontang, or whatever that place in N. Korea is called. <g>

To: Joan Osland Graffius who wrote (98437)	4/4/2003 4:08:08 PM
From: ild	Read Replies (1) \| Respond to of 132070

VASO PR at work: Unprecedented Number of Presentations on Vasomedical's EECP Therapy During the Annual Scientific Session of the American College of Cardiology Business Wire - April 04, 2003 13:32 WESTBURY, N.Y.--(BUSINESS WIRE)--April 4, 2003-- Therapy subject of a symposium, experts' session and seven presentations Vasomedical (NasdaqSmallCap:VASO) announced today that the largest number of scientific presentations on EECP(R) enhanced external counterpulsation therapy occurred during the 52nd Annual Scientific Session of the American College of Cardiology (ACC) in Chicago, Illinois March 30-April 2. The presentations continued to support the use of the therapy for treating refractory angina and heart failure patients among diverse patient populations and provided further insight into possible mechanisms of action. Photios T. Paulson, Chief Executive Officer for Vasomedical said, "We are pleased to see both the number of presentations and attendees on EECP therapy at this year's ACC. Data in these presentations continue to demonstrate the beneficial results of the use of EECP therapy among patients with few treatment options for their coronary artery disease." Gregory W. Barsness, MD, of the Mayo Clinic in Rochester, MN and Rohit R. Arora, MD, of the University of Medicine and Dentistry of New Jersey in Newark, discussed EECP as a treatment option for patients that are not candidates for interventional revascularization procedures to a large audience during a "Meet the Experts" session entitled "Treatment of Refractory Angina Pectoris." In a separate ACC symposium entitled "Strategies for the Treatment of the Nonrevascularizable Patient," Dr. Barsness presented a history of EECP along with a summary of clinical studies supporting the belief that the therapy may stimulate the growth of new vessels contributing to positive patient outcomes. In a third presentation, Dr. Barsness presented data on a study entitled "Enhanced External Counterpulsation Improves Endothelial Function in Patients with Coronary Artery Disease," demonstrating that improved endothelial cell function following EECP therapy may support the hypothesis that angiogenesis is a mechanism of action of EECP. Six poster presentations highlighted data analyzed from the International EECP Patient Registry (IEPR) maintained at the University of Pittsburgh, Graduate School of Public Health, Department of Epidemiology, Pittsburgh, PA. The presentations displayed the beneficial results of EECP among elderly patients, end stage ischemic heart disease patients, along with angina patients having co-morbid conditions such as diabetes and atrial fibrillation. In addition, other data suggest the benefits of EECP therapy are sustained for up to two years in most patients. The American College of Cardiology is a professional society of over 25,000 cardiovascular physicians and scientists from around the world that support ACC's mission, "to foster optimal cardiovascular care and disease prevention through professional education, promotion of research, leadership in the development of standards and guidelines and the formulation of health care policy."